Partner Headlines - MDVN

  1. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  2. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  3. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  4. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  5. Benzinga's Top Upgrades

    Benzinga
  6. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  7. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  8. Morning Market Movers

    Benzinga
  9. Stocks To Watch For April 1, 2014

    Benzinga
  10. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  11. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  12. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  13. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  14. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  17. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  18. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  19. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  20. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  21. Stocks Hitting 52-Week Highs

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  24. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  25. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  26. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  27. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  28. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  29. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  30. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  31. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  32. Benzinga's Top Initiations

    Benzinga
  33. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  34. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  35. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  36. Medivation Effects 2-for-1 Stock Split

    Benzinga
  37. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  38. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  39. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  40. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  41. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  42. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  43. Stocks Hitting 52-Week Highs

    Benzinga
  44. Health Care Sector Wrap

    FoxBusiness
  45. Four Winning Trades Based on Analyst Calls

    Benzinga
  46. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  47. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  48. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  49. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  50. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  51. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  52. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  53. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  54. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  55. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  56. Will Johnson & Johnson Cure Cancer?

    Benzinga
  57. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  58. Notable Put Options Activity in Medivation

    Benzinga
  59. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  60. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  61. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  62. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  63. Jefferies Raises PT on Medivation to $95

    Benzinga
  64. Wedbush Raises PT on Medivation to $81

    Benzinga
  65. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  66. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  67. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  68. Alzheimer's drug test halted

    IBD
  69. Best Biotech Stocks of 2011

    Benzinga
  70. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  71. Notable Put Options Activity in Medivation

    Benzinga
  72. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center